A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.

Robin L. Jones,Teresa Macarulla,John A. Charlson,Brian A. Van Tine,Lipika Goyal,Antoine Italiano,Christophe Massard,Mark Rosenthal,Macarena I. de la Fuente,Patricia Roxburgh,Madappa N. Kundranda,Jean-Yves Blay,Changhoon Yoo,Kate Lipford,Sanjeev Forsyth,Sylvie Guichard,Yelena Mikhailov,Blythe Thomson,Patrick Kelly,Florence Duffaud

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.

2020

e16643Background: Isocitrate dehydrogenase 1 mutations (mIDH1) are present in a variety of solid tumors resulting in production and accumulation of (R)-2-hydroxyglutarate causing DNA hypermethylati...

Keywords:

Oncology
in patient
IDH1
Pathology
Medicine
Internal medicine
single agent
Mutant
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations